TGTX
TGTX
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $161.709M ▲ | $104.189M ▲ | $390.895M ▲ | 241.727% ▲ | $2.688 ▲ | $32.692M ▼ |
| Q2-2025 | $141.148M ▲ | $87.367M ▼ | $28.187M ▲ | 19.97% ▲ | $0.19 ▲ | $37.695M ▲ |
| Q1-2025 | $120.856M ▲ | $96.693M ▲ | $5.06M ▼ | 4.187% ▼ | $0.035 ▼ | $12.281M ▼ |
| Q4-2024 | $108.185M ▲ | $62.837M ▲ | $23.331M ▲ | 21.566% ▲ | $0.16 ▲ | $32.576M ▲ |
| Q3-2024 | $83.879M | $62.104M | $3.88M | 4.626% | $0.03 | $15.164M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $251.87M ▼ | $702.613M ▲ | $426.181M ▲ | $276.432M ▲ |
| Q1-2025 | $276.24M ▼ | $656.689M ▲ | $419.4M ▲ | $237.289M ▲ |
| Q4-2024 | $311M ▼ | $577.69M ▼ | $355.326M ▼ | $222.364M ▲ |
| Q3-2024 | $341.041M ▲ | $586.014M ▲ | $393.857M ▲ | $192.157M ▲ |
| Q2-2024 | $217.252M | $401.207M | $223.639M | $177.568M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $28.187M ▲ | $7.436M ▲ | $-3.992M ▲ | $-6.443M ▼ | $-2.999M ▲ | $7.394M ▲ |
| Q1-2025 | $5.06M ▼ | $-28.715M ▼ | $-12.934M ▼ | $-6.102M ▼ | $-47.751M ▼ | $-28.74M ▼ |
| Q4-2024 | $23.331M ▲ | $-25.641M ▼ | $15.788M ▲ | $-6.072M ▼ | $-15.925M ▼ | $-25.662M ▼ |
| Q3-2024 | $3.88M ▼ | $-12.205M ▼ | $-9.334M ▼ | $134.454M ▲ | $112.915M ▲ | $-12.229M ▼ |
| Q2-2024 | $6.879M | $5.536M | $1.765M | $135K | $7.433M | $5.536M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 License Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $80.00M ▲ | $180.00M ▲ | $120.00M ▼ | $140.00M ▲ |
 Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Milestone | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
NEWS
November 28, 2025 · 7:30 AM UTC
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Read more
October 31, 2025 · 7:30 AM UTC
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
Read more
October 28, 2025 · 7:30 AM UTC
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
Read more
September 24, 2025 · 9:10 AM UTC
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
Read more
September 10, 2025 · 7:30 AM UTC
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Read more
About TG Therapeutics, Inc.
https://www.tgtherapeutics.comTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $161.709M ▲ | $104.189M ▲ | $390.895M ▲ | 241.727% ▲ | $2.688 ▲ | $32.692M ▼ |
| Q2-2025 | $141.148M ▲ | $87.367M ▼ | $28.187M ▲ | 19.97% ▲ | $0.19 ▲ | $37.695M ▲ |
| Q1-2025 | $120.856M ▲ | $96.693M ▲ | $5.06M ▼ | 4.187% ▼ | $0.035 ▼ | $12.281M ▼ |
| Q4-2024 | $108.185M ▲ | $62.837M ▲ | $23.331M ▲ | 21.566% ▲ | $0.16 ▲ | $32.576M ▲ |
| Q3-2024 | $83.879M | $62.104M | $3.88M | 4.626% | $0.03 | $15.164M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $251.87M ▼ | $702.613M ▲ | $426.181M ▲ | $276.432M ▲ |
| Q1-2025 | $276.24M ▼ | $656.689M ▲ | $419.4M ▲ | $237.289M ▲ |
| Q4-2024 | $311M ▼ | $577.69M ▼ | $355.326M ▼ | $222.364M ▲ |
| Q3-2024 | $341.041M ▲ | $586.014M ▲ | $393.857M ▲ | $192.157M ▲ |
| Q2-2024 | $217.252M | $401.207M | $223.639M | $177.568M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $28.187M ▲ | $7.436M ▲ | $-3.992M ▲ | $-6.443M ▼ | $-2.999M ▲ | $7.394M ▲ |
| Q1-2025 | $5.06M ▼ | $-28.715M ▼ | $-12.934M ▼ | $-6.102M ▼ | $-47.751M ▼ | $-28.74M ▼ |
| Q4-2024 | $23.331M ▲ | $-25.641M ▼ | $15.788M ▲ | $-6.072M ▼ | $-15.925M ▼ | $-25.662M ▼ |
| Q3-2024 | $3.88M ▼ | $-12.205M ▼ | $-9.334M ▼ | $134.454M ▲ | $112.915M ▲ | $-12.229M ▼ |
| Q2-2024 | $6.879M | $5.536M | $1.765M | $135K | $7.433M | $5.536M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
| License Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Product | $80.00M ▲ | $180.00M ▲ | $120.00M ▼ | $140.00M ▲ |
| Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Milestone | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
NEWS
November 28, 2025 · 7:30 AM UTC
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Read more
October 31, 2025 · 7:30 AM UTC
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
Read more
October 28, 2025 · 7:30 AM UTC
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
Read more
September 24, 2025 · 9:10 AM UTC
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
Read more
September 10, 2025 · 7:30 AM UTC
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Read more
CEO
Michael S. Weiss
Compensation Summary
(Year 2024)
CEO
Michael S. Weiss
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-04-30 | Reverse | 4:225 |
| 2011-07-19 | Reverse | 1:50 |
| 2011-07-14 | Reverse | 1:50 |
| 2003-09-29 | Reverse | 1:5 |
Price Target
Institutional Ownership
PICTET ASSET MANAGEMENT HOLDING SA
1.61M Shares
$53.534M
PICTET ASSET MANAGEMENT LTD
1.601M Shares
$53.257M
BLACKROCK FUND ADVISORS
1.179M Shares
$39.198M
CARILLON TOWER ADVISERS, INC.
992.041K Shares
$32.995M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
968.608K Shares
$32.216M
EVENTIDE ASSET MANAGEMENT, LLC
954.531K Shares
$31.748M
PUBLIC SECTOR PENSION INVESTMENT BOARD
529.271K Shares
$17.604M
PENN CAPITAL MANAGEMENT COMPANY, LLC
521.26K Shares
$17.337M
BRIDGEWATER ASSOCIATES, LP
342.149K Shares
$11.38M
GHOST TREE CAPITAL, LLC
310K Shares
$10.311M
VOLORIDGE INVESTMENT MANAGEMENT, LLC
212.906K Shares
$7.081M
RAFFERTY ASSET MANAGEMENT, LLC
212.058K Shares
$7.053M
EAGLE ASSET MANAGEMENT INC
168.795K Shares
$5.614M
M28 CAPITAL MANAGEMENT LP
161.6K Shares
$5.375M
TEACHERS ADVISORS, LLC
149.353K Shares
$4.967M
BLACKROCK INVESTMENT MANAGEMENT, LLC
146.838K Shares
$4.884M
FIRST TRUST ADVISORS LP
143.703K Shares
$4.78M
CASTLEARK MANAGEMENT LLC
140.316K Shares
$4.667M
GREAT WEST LIFE ASSURANCE CO /CAN/
132.284K Shares
$4.4M
TIAA CREF INVESTMENT MANAGEMENT LLC
127.307K Shares
$4.234M
Summary
Only Showing The Top 20